Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
P/E ratio for Lexicon Pharmaceuticals, Inc. (LXRX)
P/E ratio as of 2023: -1.91
According to Lexicon Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.91. At the end of 2022 the company had a P/E ratio of -3.07.
P/E ratio history for Lexicon Pharmaceuticals, Inc. from 1999 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.91 |
| 2022 | -3.07 |
| 2021 | -6.50 |
| 2020 | -5.40 |
| 2019 | 3.39 |
| 2018 | -5.82 |
| 2017 | -8.05 |
| 2016 | -10.16 |
| 2015 | -294.49 |
| 2014 | -4.85 |
| 2013 | -8.87 |
| 2012 | -9.82 |
| 2011 | -3.78 |
| 2010 | -4.28 |
| 2009 | -2.99 |
| 2008 | -2.49 |
| 2007 | -5.14 |
| 2006 | -4.45 |
| 2005 | -6.43 |
| 2004 | -10.42 |
| 2003 | -5.21 |
| 2002 | -4.14 |
| 2001 | -16.47 |
| 2000 | -26.62 |
| 1999 | -36.80 |